Remus Pharmaceuticals Limited

NSEI:REMUS Stock Report

Market Cap: ₹14.4b

Remus Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NSEI:REMUS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
24 Sep 24Buy₹2,688,995Arpit ShahIndividual1,000₹2,689.00
18 Sep 24Buy₹2,147,080Renosen Pharmaceuticals Private LimitedCompany900₹2,405.00
16 Aug 24Buy₹4,552,800Renosen Pharmaceuticals Private LimitedCompany2,000₹2,276.40
05 Aug 24Buy₹7,344,280Renosen Pharmaceuticals Private LimitedCompany3,600₹2,093.00
05 Aug 24Buy₹5,225,990Arpit ShahIndividual2,500₹2,095.00
12 Jun 24Buy₹1,027,235Renosen Pharmaceuticals Private LimitedCompany500₹2,065.00
04 Jun 24Buy₹3,617,790Renosen Pharmaceuticals Private LimitedCompany2,100₹1,820.88
03 Jun 24Sell₹2,743,549Roma ShahIndividual1,500₹1,829.03
29 May 24Buy₹1,418,923Renosen Pharmaceuticals Private LimitedCompany800₹1,794.94
28 May 24Buy₹3,756,569Renosen Pharmaceuticals Private LimitedCompany2,100₹1,819.06
22 Mar 24Buy₹730,699Renosen Pharmaceuticals Private LimitedCompany500₹1,461.40
15 Mar 24Buy₹267,450Renosen Pharmaceuticals Private LimitedCompany200₹1,337.25
15 Mar 24Buy₹267,450Renosen Pharmaceuticals Private LimitedCompany200₹1,337.25
12 Mar 24Buy₹630,700Renosen Pharmaceuticals Private LimitedCompany500₹1,275.00
06 Mar 24Buy₹565,175Renosen Pharmaceuticals Private LimitedCompany400₹1,424.75
05 Mar 24Buy₹1,116,545Renosen Pharmaceuticals Private LimitedCompany800₹1,399.99
20 Feb 24Buy₹1,360,648Renosen Pharmaceuticals Private LimitedCompany800₹1,700.81
13 Feb 24Buy₹2,070,000Renosen Pharmaceuticals Private LimitedCompany1,200₹1,725.00
24 Jan 24Buy₹1,247,666Arpit ShahIndividual800₹1,562.13
24 Jan 24Buy₹307,499Renosen Pharmaceuticals Private LimitedCompany200₹1,537.49
20 Jan 24Buy₹158,750Arpit ShahIndividual100₹1,587.50
19 Jan 24Buy₹3,157,050Arpit ShahIndividual2,000₹1,578.52
18 Jan 24Buy₹3,596,673Renosen Pharmaceuticals Private LimitedCompany2,200₹1,656.35
12 Jan 24Buy₹2,061,375Renosen Pharmaceuticals Private LimitedCompany1,200₹1,717.81
03 Jan 24Buy₹2,952,000Arpit ShahIndividual1,600₹1,845.00
03 Jan 24Buy₹2,943,245Renosen Pharmaceuticals Private LimitedCompany1,600₹1,843.11

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of REMUS?
Owner TypeNumber of SharesOwnership Percentage
Private Companies53,3000.905%
General Public1,722,30029.2%
Individual Insiders4,116,40069.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 11 shareholders own 70.77% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
17.6%
Arpit Shah
1,038,500₹2.5b0.34%no data
17.2%
Roma Shah
1,012,400₹2.5b0%no data
17%
Swapnil Shah
1,000,000₹2.4b0%no data
17%
Anar Shah
1,000,000₹2.4b0%no data
0.9%
Renosen Pharmaceuticals Private Limited
53,300₹130.2m13.9%no data
0.27%
Vishrut Pathak
16,000₹39.1m0%no data
0.27%
Rekha Kumar
16,000₹39.1m0%no data
0.24%
Deval Patel
14,000₹34.2m0%no data
0.18%
Parag Shah
10,700₹26.1m0%no data
0.14%
Balwant Purohit
8,000₹19.5m0%no data
0.014%
Anjali Shah
800₹2.0m0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 20:20
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Remus Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution